Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ikena Oncology Inc. Common Stock
IKNA | US
1.69
USD-0.02
-1.17%
IKNA | US
About Ikena Oncology Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.69
Open
1.71
High
1.71
Low
1.68
Ikena Oncology Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930 a paralog selective inhibitor of the transcriptional enhanced associate domain a transcription factor in the Hippo signaling pathway. It also develops IK-595 designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175 a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors including urothelial carcinomas. Ikena Oncology Inc. was incorporated in 2016 and is headquartered in Boston Massachusetts.
View LessIKNA | US
Risk
13.1
Sharpe
-0.64
Luna's Score
45/100
Recommendation
Sell
Luna says (IKNA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
9.7%1 month
13.1%3 months
27.0%6 months
51.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.58
Debt to equity
0.06
Debt to assets
0.06
Ent. to EBITDA
-0.54
Ent. to rev.
0.93
PEG
-
Other Fundamentals
EBITDA
-71.34M
MarketCap
81.56M
MarketCap(USD)
81.56M
Div. yield
-
Op. margin
-3.92K
Erngs. growth
-
Rev. growth
-87.90
Ret. on equity
-44.54
Short ratio
5.01
Short perc.
0.54
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.11
Range1M
0.11
Range3M
0.27
Volumes: Market Activity
Rel. volume
0.40
Price X volume
24.78K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.54 | - | Cheaper |
| Ent. to Revenue | 0.93 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.58 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 26.99 | - | Lower Risk |
| Debt to Equity | 0.06 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 81.56M | - | Emerging |
